High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.

Adriano Pellicelli Vincenzo Messina Valerio GiannelliMarco DistefanoValeria Pace PalittiPascal VignallyPierluigi TarquiniAntonio IzziAlessandra MorettiSergio BabudieriSerena Dell'IsolaMassimo MarignaniGaetano ScifoVincenzo IovinellaGiuseppe CaritiMaurizio PompiliFrancesco Di CandiloLuca Fontanella Giuseppe Maria Ettorre Giovanni Vennarecci Antonio Massimo Ippolito Giorgio Barbarini

Published in: Gut and liver (2021)

We found that the DCV/SOF/RBV flat-dose regimen is an effective treatment in terms of efficacy and safety in patients with G3-HCV compensated or decompensated cirrhosis. Therefore, antiviral regimens without RBV should be restricted only to naïve patients with G3-HCV compensated cirrhosis who have a clear contraindication for RBV.

Keyphrases

hepatitis c virus
ejection fraction
human immunodeficiency virus
end stage renal disease
heart failure
newly diagnosed
combination therapy
hepatitis c virus infection
patient reported outcomes
hiv infected
liver failure
antiretroviral therapy